Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;167(2):168-182.
doi: 10.1111/jnc.15944. Epub 2023 Sep 7.

Cerebrospinal fluid and blood serum biomarkers in neurodegenerative proteinopathies: A prospective, open, cross-correlation study

Dorota Koníčková  1   2 , Kateřina Menšíková  1   2 , Kateřina Klíčová  1   2 , Monika Chudáčková  1   2 , Michaela Kaiserová  1   2 , Hana Přikrylová  1   3 , Pavel Otruba  1   2 , Martin Nevrlý  1   2 , Petr Hluštík  1   2 , Eva Hényková  1   2   4 , Michal Kaleta  1   2   4 , David Friedecký  5 , Radoslav Matěj  6 , Miroslav Strnad  1   2 , Ondřej Novák  4 , Lucie Plíhalová  7 , Raymond Rosales  8 , Carlo Colosimo  9 , Petr Kaňovský  1   2
Affiliations

Cerebrospinal fluid and blood serum biomarkers in neurodegenerative proteinopathies: A prospective, open, cross-correlation study

Dorota Koníčková et al. J Neurochem. 2023 Oct.

Abstract

Neurodegenerative diseases are a broad heterogeneous group affecting the nervous system. They are characterized, from a pathophysiological perspective, by the selective involvement of a subpopulation of nerve cells with a consequent clinical picture of a disease. Clinical diagnoses of neurodegenerative diseases are quite challenging and often not completely accurate because of their marked heterogeneity and frequently overlapping clinical pictures. Efforts are being made to define sufficiently specific and sensitive markers for individual neurodegenerative diseases or groups of diseases in order to increase the accuracy and speed of clinical diagnosis. Thus said, this present research aimed to identify biomarkers in the cerebrospinal fluid (CSF) and serum (α-synuclein [α-syn], tau protein [t-tau], phosphorylated tau protein [p-tau], β-amyloid [Aβ], clusterin, chromogranin A [chromogrA], cystatin C [cyst C], neurofilament heavy chains [NFH], phosphorylated form of neurofilament heavy chains [pNF-H], and ratio of tau protein/amyloid beta [Ind tau/Aβ]) that could help in the differential diagnosis and differentiation of the defined groups of α-synucleinopathies and four-repeat (4R-) tauopathies characterized by tau protein isoforms with four microtubule-binding domains. In this study, we analyzed a cohort of 229 patients divided into four groups: (1) Parkinson's disease (PD) + dementia with Lewy bodies (DLB) (n = 82), (2) multiple system atrophy (MSA) (n = 25), (3) progressive supranuclear palsy (PSP) + corticobasal syndrome (CBS) (n = 30), and (4) healthy controls (HC) (n = 92). We also focused on analyzing the biomarkers in relation to each other with the intention of determining whether they are useful in distinguishing among individual proteinopathies. Our results indicate that the proposed set of biomarkers, when evaluated in CSF, is likely to be useful for the differential diagnosis of MSA versus 4RT. However, these biomarkers do not seem to provide any useful diagnostic information when assessed in blood serum.

Keywords: biomarkers; blood serum; cerebrospinal fluid; neurodegenerative diseases; tauopathies; α-synucleinopathies.

PubMed Disclaimer

References

REFERENCES

    1. Aguirre, J. D., Dunkerley, K. M., Lam, R., Rusal, M., & Shaw, G. S. (2018). Impact of altered phosphorylation on loss of function of juvenile parkinsonism-associated genetic variants of the E3 ligase parkin. Journal of Biological Chemistry, 293(17), 6337-6348. https://doi.org/10.1074/jbc.RA117.000605
    1. Alexander, S. K., Rittmen, T., Xuereb, J. H., Bak, T. H., Hodges, J. R., & Rowe, J. B. (2014). Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 85(8), 925-929. https://doi.org/10.1136/jnnp-2013-307035
    1. Andersen, A. D., Binzer, M., Stenager, E., & Gramsbergen, J. B. (2017). Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review. Acta Neurologica Scandinavica, 135(1), 34-56. https://doi.org/10.1111/ane.12590
    1. Angelopoulou, E., Paudel, Y. N., Shaikh, M. F., & Piperi, C. (2020). Fractalkine (CX3CL1) signaling and neuroinflammation in Parkinson's disease: Potential clinical and therapeutic implications. Pharmacological Research, 158, 104930. https://doi.org/10.1016/j.phrs.2020.104930
    1. Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., Josephs, K. A., Kertesz, A., Lee, S. E., Miller, B. L., Raich, S. G., Rilez, D. E., Tolosa, E., Tröster, A. I., Vidaihlet, M., & Weiner, W. J. (2013). Criteria for the diagnosis of corticobasal degeneration. Neurology, 80(5), 496-503. https://doi.org/10.1212/WNL.0b013e31827f0fd1

LinkOut - more resources